BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 9627113)

  • 21. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
    Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
    Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of p53 gene in gastric carcinoma in Taiwan.
    Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
    Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53AIP1 expression can be a prognostic marker in non-small cell lung cancer.
    Yamashita SI; Masuda Y; Yoshida N; Matsuzaki H; Kurizaki T; Haga Y; Ikei S; Miyawaki M; Kawano Y; Chujyo M; Kawahara K
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):148-51. PubMed ID: 17851056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
    Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Donati V; Fontanini G
    Cancer Invest; 2008 Mar; 26(2):168-72. PubMed ID: 18259947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of mutation types of p53 gene and possible carcinogenic factors in lung cancer].
    Gao ZQ; Gao Z; Zhang X
    Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Mar; 31(2):88-91. PubMed ID: 9812619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases.
    Hashimoto T; Kobayashi Y; Ishikawa Y; Tsuchiya S; Okumura S; Nakagawa K; Tokuchi Y; Hayashi M; Nishida K; Hayashi S; Hayashi J; Tsuchiya E
    Cancer Res; 2000 Nov; 60(22):6472-8. PubMed ID: 11103815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
    Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
    Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients.
    Murata M; Tagawa M; Kimura H; Kakisawa K; Shirasawa H; Fujisawa T
    Int J Oncol; 1998 Mar; 12(3):577-81. PubMed ID: 9472095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis of lymph node micrometastases in human lung carcinoma: determination of p53 gene mutations by polymerase chain reaction-temperature gradient gel electrophoresis (PCR-TGGE)].
    Xu ML; Wu BQ; Zhong HH; Yang X; Heng WJ
    Ai Zheng; 2004 Jul; 23(7):794-8. PubMed ID: 15248914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.